Differences in glycosylation of intracellular proteins between benign and malignant thyroid neoplasms

Cancer Letters

Volumn 196, Issue 1, 2003, Pages 101-107

  Krzeslak A ^a   Pomorski, L ^b   Gaj, Z ^a   Lipinska A ^a  

^a UNIVERSITY OF LODZ   (Poland)

^b MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Enzyme linked lectino solid phase assay; Intracellular glycoproteins; Lectins; Thyroid lesions

Indexed keywords

AGGLUTININ; CELL PROTEIN; LECTIN; NUCLEAR PROTEIN; VEGETABLE PROTEIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ERYTHRINA; FEMALE; HUMAN; HUMAN TISSUE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN BLOTTING; PROTEIN GLYCOSYLATION; PROTEIN ISOLATION; PROTEIN PROTEIN INTERACTION; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RICINUS COMMUNIS; THYROID CARCINOMA; THYROID TUMOR;

RICINUS COMMUNIS; UNIDENTIFIED AGENTS;

EID: 0038645282     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(03)00206-4     Document Type: Article

References (33)

1. Drickamer K., Taylor M.E. Evolving views of protein glycosylation. TIBS. 23:1998;321-324.
2. Wormald M.R., Dwek R.A. Glycoproteins: glycan presentation and protein-fold stability. Structure. 7:1999;155-160.
3. Krzeslak A., Lipinska A. Effect of carbohydrate moieties on the stability of nuclear glycoproteins from hamster liver. Cytobios. 89:1997;161-171.
4. Comer F.I., Hart G.W. O-GlcNAc and the control of gene expression. Biochim. Biophys. Acta. 1473:1999;161-171.
5. Comer F.I., Hart G.W. O-glycosylation of nuclear and cytosolic proteins. Dynamic interplay between O-GlcNAc and O-phosphate. J. Biol. Chem. 275:2000;179-182.
6. Wells L., Vosseller K., Hart G.W. Glycosylation of nucleocytoplasmic proteins: signal transduction and O-GlcNAc. Science. 291:2001;2376-2378.
7. Vosseller K., Wells L., Hart G.W. Nucleocytoplasmic O-glycosylation: O-GlcNAc and functional proteomics. Biochimie. 83:2001;575-581.
8. Duverger E., Pellerin-Mendes C., Mayer R., Roche A.-C., Monsigny M. Nuclear import of glycoconjugates is distinct from the classical NLS pathway. J. Cell. Sci. 108:1995;1325-1332.
9. Kim Y.J., Varki A. Perspectives on the significance of altered glycosylation of glycoproteins in cancer. Glycoconjugate J. 14:1997;569-576.
10. Dennis J.W., Granovsky M., Warren C.E. Protein glycosylation in development and disease. BioEssays. 21:1999;412-421.
11. Ho S.B., Kim Y.S. Glycoproteins and glycosylation changes in cancer. Bertino J.R. Encyclopedia of Cancer. 1996;744-759 Academic Press, New York.
12. Dennis J.W., Granovsky M., Warren C. Glycoprotein glycosylation and cancer progression. Biochim. Biophys. Acta. 1473:1999;21-34.
13. Brockhausen I. Pathways of Oglycan biosynthesis in cancer cells. Biochim. Biophys. Acta. 1473:1999;67-95.
14. Chauveau J., Moulé Y., Rouiller C. Isolation of pure and unaltered liver nuclei morphology and biochemical composition. Exp. Cell. Res. 11:1956;317-321.
15. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 227:1970;680-685.
16. Fairbanks G., Steck T.L., Wallach D.F. Electrophoretic analysis of the major polypeptides of the human erythrocyte membrane. Biochemistry. 10:1971;2606-2617.
17. Towbin H., Staehelin T., Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets; procedure and some applications. Proc. Natl. Acad. Sci. USA. 76:1979;4350-4355.
18. 4 isolectin for the detection of α-D-galactopyranosyl end groups. Anal. Biochem. 130:1983;437-444.
19. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurements with the Folin phenol reagent. J. Biol. Chem. 193:1951;262-275.
20. Xu X.-C., El-Naggar A.K., Lotan R. Differential expression of galectin-1 and galectin-3 in thyroid tumors. Potential diagnostic implications. Am. J. Pathol. 147:1995;815-822.
21. Fernandez P.L., Merino M.J., Gomez M., et al. Galectin-3 and laminin expression in neoplastic and non-neoplastic thyroid tissue. J. Pathol. 181:1997;80-86.
22. Orlandi F., Saggiorato E., Pivano G., et al. Galectin-3 is a presurgical marker of human thyroid carcinoma. Cancer Res. 58:1998;3015-3020.
23. Inohara H., Honjo Y., Yoshii T., et al. Expression of galectin-3 in fine-needle aspirates as a diagnostic marker differentiating benign from malignant thyroid neoplasms. Cancer. 11:1999;2475-2484.
24. Kawachi K., Matsushita Y., Yonezawa S., et al. Galectin-3 expression in various thyroid neoplasms and its possible role in metastasis formation. Human Pathol. 31:2000;428-433.
25. Yoshii T., Inohara H., Takenaka Y., et al. Galectin-3 maintains the transformed phenotype of thyroid papillary carcinoma cells. Int. J. Oncol. 18:2001;787-792.
26. Coli A., Bigotti G., Zuccheti F., Negro F., Massi G. Galectin-3, a marker of well differentiated thyroid carcinoma, is expressed in thyroid nodules with cytological atypia. Histopathology. 40:2002;80-87.
27. Hermann M.E., LiVolsi V.A., Pasha T.L., Roberts S.A., Wojcik E.M., Baloch Z.W. Immunohistochemical expression of galectin-3 in benign and malignant thyroid lesions. Arch. Pathol. Lab. Med. 126:2002;710-713.
28. Danguy A., Camby I., Kiss R. Galectins and cancer. Biochim. Biophys. Acta. 1572:2002;285-293.
29. Wada J., Makino H. Galectins, galactoside-binding mammalian lectins: clinical application of multi-functional proteins. Acta. Med. Okayama. 55:2001;11-17.
30. Rabinovich G.A., Baum L.G., Tinari N., et al. Galectins and their ligands: amplifiers, silencers or tuners of the inflammatory response? Trends Immunol. 23:2002;313-320.
31. Hughes R.C. Galectins as modulators of cell adhesion. Biochimie. 83:2001;667-676.
32. Debray H. Use of lectins. Verbert A. Methods on Glycoconjugates Harwood. 1995:1995;103-133 Harwood Academic Publishers GmbH, Switzerland.
33. Saggiorato E., Cappia S., De Giuli P., et al. Galectin-3 as a presurgical immunocytodiagnostic marker of minimally invasive follicular thyroid carcinoma. J. Clin. Endocrinol. Metabol. 86:2001;5152-5158.